Valeant Pharma (VRX) proposes to buy Cephalon (CEPH) for $73 per share
Tweet
Share
E-mailSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Holcim to acquire Fermacell from James Hardie for EUR 840M
- Morgan Stanley sees a buying opportunity in this data center stock
- UBS flags this name, sees "significant potential for stock outperformance"
Create E-mail Alert Related Categories
Hot List, Hot M&A, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
